erlotinib hydrochloride has been researched along with Intradural-Extramedullary Spinal Cord Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belaid, I; Ben Ayed, F; Debbiche, G; Jlassi, H; Rais, H | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
1 review(s) available for erlotinib hydrochloride and Intradural-Extramedullary Spinal Cord Neoplasms
| Article | Year |
|---|---|
[Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Disease Progression; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Quinazolines; Radiography; Spinal Cord Neoplasms | 2013 |
1 other study(ies) available for erlotinib hydrochloride and Intradural-Extramedullary Spinal Cord Neoplasms
| Article | Year |
|---|---|
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |